Gaudium IVF and Women Health Ltd (GAUDIUMIVF)
🎯 Key Takeaways
- Gaudium IVF and Women Health Ltd is in a high-growth, capital-intensive expansion phase within India's underpenetrated fertility healthcare market. Management is prioritizing market penetration through new IVF hubs and hospital projects over short-term profitability, supported by a strong balance sheet and disciplined capital allocation.
- Revenue declined 36.1% QoQ to ₹19 in Q1FY27.
- ⚠️ 1) Expansion execution risk: Delays or cost overruns in launching new hubs and the Lucknow hospital could strain finances and dilute returns. 2) Compe
📖 The Story
Gaudium IVF and Women Health Ltd is in a high-growth, capital-intensive expansion phase within India's underpenetrated fertility healthcare market. Management is prioritizing market penetration through new IVF hubs and hospital projects over short-term profitability, supported by a strong balance sheet and disciplined capital allocation. The company has demonstrated consistent revenue growth and clinical excellence, though profitability is being temporarily pressured by strategic investments.
📰 What's Happening
In Q1FY27 (June 2026), the company reported ₹19.4 Cr revenue (+9.13% YoY) and launched its first new IVF hub in South Extension, New Delhi, while approving a ₹15 Cr women's hospital in Lucknow. Management highlighted AI-powered embryology tools (SiD/ERICA) achieving 62% first-attempt success rates, underscoring clinical differentiation. Expansion plans include 10 new hubs by FY27 end, with 8 scheduled for FY28 and 1 for FY29. Despite EBITDA and PAT declines due to expansion costs, revenue growth and clinical outcomes validate the investment thesis. The board reaffirmed its focus on scaling operations responsibly within India's fragmented fertility market.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 27 | 18 | 32 | 25 | 30 | 19 |
| Operating Profit | 8 | 4 | 13 | 6 | 12 | 2 |
| OPM % | 31.1% | 24.7% | 41.4% | 24.7% | 38.0% | 8.8% |
| Net Profit | 6 | 3 | 9 | 4 | 8 | 2 |
| EPS | ₹1.05 | ₹0.51 | ₹1.53 | ₹0.59 | ₹1.34 | ₹0.25 |
Revenue has shown sequential and YoY growth, rising from ₹18 Cr in Q2FY25 to ₹19.4 Cr in Q1FY27, driven by mature hub performance and international patient traction. However, profitability has declined sharply — PAT fell 42.27% YoY to ₹1.8 Cr in Q1FY27, and OPM dropped from 38% in Q3FY26 to 8.8% in Q1FY27 — reflecting heavy investment in expansion. Operating costs are increasing in line with management's stated strategy of scaling hubs and launching the Lucknow hospital, with capital expenditure deferred to FY27-28. The trend indicates a deliberate trade-off: short-term margin compression for long-term market share gains in a high-growth, low-penetration sector.
🔮 Management Outlook & What's Next
Management explicitly frames expansion as the priority, with plans to add 10 hubs by FY27 end and establish a new women's hospital in Lucknow at a ₹15 Cr cost. They cite AI-driven clinical tools improving success rates to 62% as a sustainable differentiator. While acknowledging short-term profitability pressure from expansion costs, they maintain confidence in a debt-light model and responsible capital deployment. No formal financial guidance beyond operational milestones was provided, but the focus remains on scaling infrastructure while preserving clinical excellence and regulatory compliance.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 31 | 31 | 36 |
| Reserves | 16 | 28 | 116 |
| Borrowings | 19 | 24 | 25 |
| Total Liabilities | 89 | 107 | 193 |
| Fixed Assets | 26 | 8 | 9 |
| Investments | 5 | 5 | 5 |
| Total Assets | 89 | 107 | 193 |
The balance sheet remains robust, with equity growing from ₹31 Cr (Mar 2025) to ₹36 Cr (Mar 2026) and reserves increasing from ₹16 Cr to ₹116 Cr, indicating strong retained earnings. Borrowings are minimal and stable at ₹25 Cr, reflecting a conservative capital structure. The company holds significant liquidity, with IPO proceeds of ₹90 Cr partially deployed — ₹25.34 Cr utilized by June 2026, including ₹5.76 Cr for the Lucknow hospital — while the remainder is parked in fixed deposits and general corporate purposes. This suggests ample runway for expansion without dilutive financing, supporting the strategy of funding growth through internal resources and prudent leverage.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +9 |
| Investing | -15 |
| Financing | +2 |
| Net Cash Flow | -5 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 100.0% | 71.3% | 71.3% |
| FII | 0.0% | 6.7% | 3.0% |
| DII | 0.0% | 2.6% | 2.2% |
| Public | 0.0% | 14.7% | 16.8% |
| # Shareholders | 7 | 19,854 | 21,910 |
Promoter holding remains stable at 71.29% in Q1FY27, indicating strong confidence from founders. Institutional interest is emerging, with FII ownership rising from 0% in Q2FY26 to 3.02% and DII from 0% to 2.22% in Q1FY27, suggesting growing institutional confidence. The increase in shareholder count from 7 to 19,854 to 21,910 also reflects broader retail interest. No pledging or significant dilution is evident, and the rise in institutional participation may signal improving market sentiment toward the company’s growth trajectory.
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.27 L Cr | 60.9 | 22.1% | 22.9% | 0.60 |
| MAXHEALTH | 1.01 L Cr | 69.2 | 14.4% | 13.6% | 0.27 |
| MANIPALHOS | 94,201 | — | — | — | 1.25 |
| FORTIS | 66,987 | 63.9 | 13.3% | 10.8% | 0.29 |
| ASTERDM | 66,504 | 123.5 | 12.9% | 8.6% | 0.17 |
| MEDANTA | 38,921 | 69.9 | 21.9% | 16.3% | 0.10 |
| NH | 38,161 | 46.5 | 13.7% | 18.0% | 1.07 |
| KIMS | 32,292 | 150.8 | 9.7% | 8.7% | 1.44 |
| LALPATHLAB | 32,009 | 46.0 | 29.6% | 21.8% | 0.00 |
| POLYMED | 17,610 | 55.9 | 15.1% | 11.3% | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Expansion execution risk: Delays or cost overruns in launching new hubs and the Lucknow hospital could strain finances and dilute returns. 2) Competitive pricing pressure: Rapid market entry by peers may force discounting, threatening margins in a price-sensitive segment. 3) Clinical dependency: Success hinges on maintaining AI tool efficacy and clinical outcomes; any degradation could erode differentiation. 4) Regulatory scrutiny: As a healthcare provider, compliance with evolving fertility treatment regulations and data privacy norms poses ongoing operational risk.
📋 Recent Filings
-
🔴 annual report 3 September 2026My answer is yes.
-
🔴 annual report 3 September 2026Gaudium IVF and Women Health Limited announced that physical letters have been dispatched to shareholders without registered email addresses, directin...
-
🟡 Board Meeting 3 September 2026Gaudium IVF and Women Health Ltd will hold its 11th AGM on September 28, 2026, via video conference, where shareholders will approve the adoption of a...
-
Announcement 19 August 2026Gaudium IVF reported 9.1% YoY revenue growth to ₹19.4 crores in Q1 FY27, driven by patient volume and international demand, though EBITDA margin moder...
-
🔴 Financial Results 13 August 2026Gaudium IVF reported Q1FY27 revenue of ₹19.4 Cr, up 9.13% YoY, driven by mature hub growth and international patient traction. EBITDA fell 52.96% YoY ...
-
🟡 deviation variation 13 August 2026Gaudium IVF and Women Health Limited announced its Q1 FY2026 unaudited financial results on August 13, 2026, reporting revenue of **₹1,480.09 lakhs** ...
-
🔴 Financial Results 13 August 2026Gaudium IVF and Women Health Limited announced on August 13, 2026, that CAx SKGN& Associates LLP was appointed as the new independent auditor followin...
-
🟡 Board Meeting 13 August 2026The Board approved unaudited Q1 FY2026 results showing ₹2,050.02 lakhs revenue and [amount context mismatch] lakhs profit after tax, while reappointin...
-
🔴 offer document 13 August 2026The Monitoring Agency Report for the quarter ended June 30, 2026 confirms that Gaudium IVF and Women Health Limited has utilized Rs. 25.34 crore of th...
-
Announcement 11 August 2026Gaudium IVF and Women Health Limited announced an earnings conference call for Q1 FY27 results on August 14, 2026 at 2:00 PM IST to discuss unaudited ...
🧠 Analyst's Read
Gaudium IVF is executing a capital-intensive growth strategy in a structurally attractive healthcare niche, with strong clinical fundamentals and improving institutional interest. Investors should monitor the pace and capital efficiency of hub rollouts, especially the Lucknow hospital, and the sustainability of margin recovery beyond FY27 as expansion phases in. The company’s ability to convert scale into durable profitability will be the key inflection point.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-13.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when GAUDIUMIVF files new disclosures
Track GAUDIUMIVF filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track GAUDIUMIVF — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd